SIHUAN PHARM(00460.HK)

Last Updated 08:00:00
longbridge loading
Company Encyclopedia
View More
name
SIHUAN PHARM
00460.HK
Sihuan Pharmaceutical Holdings Group Ltd., an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical and medical aesthetic products in the People’s Republic of China and the United States. It operates through three segments: Medical Aesthetic Products, Innovative Medicine and Other Medicine, and Generic Medicine. The company offers filling, shaping, supporting, supplementing, optoelectronic device, body sculpturing, skin care, and others, as well as non- or minimally invasive medical aesthetics comprehensive solutions. It also provides drugs in the oncology, metabolism, diabetes, cardiovascular and cerebrovascular, modern Chinese medicine, and industrial hemp therapeutic areas.
1.235 T
00460.HKMarket value -Rank by Market Cap -/-

Financial Score

19/05/2026 Update
C
PharmaceuticalsIndustry
Industry Ranking25/53
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE3.52%C
    • Profit Margin6.86%B
    • Gross Margin68.83%A
  • Growth ScoreA
    • Revenue YoY39.04%A
    • Net Profit YoY183.74%A
    • Total Assets YoY15.45%B
    • Net Assets YoY45.73%A
  • Cash ScoreC
    • Cash Flow Margin-13.11%D
    • OCF YoY39.04%A
  • Operating ScoreD
    • Turnover0.24D
  • Debt ScoreC
    • Gearing Ratio40.68%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Sihuan’s Xuanzhu Biopharm Completes Full H Share Circulation in Hong Kong

    Tip Ranks·
    HK
    00460
    +3.74%
    HK
    02575
    -1.09%
    Tip Ranks·
    HK
    00460
    +3.74%
    HK
    02575
    -1.09%

    Sihuan’s NG-350A Shows Promising Early Results in Rectal Cancer Trial

    Tip Ranks·
    HK
    00460
    +3.74%
    Tip Ranks·
    HK
    00460
    +3.74%

    Sihuan’s Xuanzhu Unit Posts Strong Phase III Lung Cancer Data for ALK Inhibitor Dirozalkib

    Tip Ranks·
    HK
    00460
    +3.74%
    HK
    02575
    -1.09%
    US
    FBT
    +0.63%
    Tip Ranks·
    HK
    00460
    +3.74%
    HK
    02575
    -1.09%
    US
    FBT
    +0.63%

    Xuanzhu Biopharm Wins Green Light for Phase III Anaprazole Trial in H. pylori

    Tip Ranks·
    HK
    02575
    -1.09%
    SH
    560600
    0.00%
    SZ
    159506
    0.00%
    Tip Ranks·
    HK
    02575
    -1.09%
    SH
    560600
    0.00%
    SZ
    159506
    0.00%

    Sihuan Pharmaceutical Holdings Group (SHPHF) Gets a Buy from Citic Securities

    Tip Ranks·
    HK
    00460
    +3.74%
    Tip Ranks·
    HK
    00460
    +3.74%
    © 2026 Longbridge｜Disclaimer